{"id":63098,"date":"2026-05-13T13:02:46","date_gmt":"2026-05-13T11:02:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/"},"modified":"2026-05-13T13:02:46","modified_gmt":"2026-05-13T11:02:46","slug":"liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/","title":{"rendered":"Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease"},"content":{"rendered":"<div>\n<p>\n<i>Data expands mechanistic and translational evidence for selective in vivo programming of monocytes and macrophages, potent peripheral B-cell depletion, and a differentiated cytokine profile<\/i><\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260513069585\/en\/2802829\/5\/Liberate_Bio_Logo_Horizontal-2color.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260513069585\/en\/2802829\/22\/Liberate_Bio_Logo_Horizontal-2color.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260513069585\/en\/2802829\/5\/Liberate_Bio_Logo_Horizontal-2color.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260513069585\/en\/2802829\/21\/Liberate_Bio_Logo_Horizontal-2color.jpg\"><\/a><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;<b>Liberate Bio, Inc.<\/b>, a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, today announced new pre-clinical data supporting LIB820, the company\u2019s lead <i>in vivo<\/i> CAR-M program for autoimmune disease. LIB820 is Liberate\u2019s first-in-human (FIH) study and is currently on track for initiation at the end of 2026. The data will be presented at the <i>American Society of Gene and Cell Therapies <\/i>conference in Boston by Dr. Walter R. Strapps, CSO of Liberate Bio.<\/p>\n<p>\nLIB820 is Liberate\u2019s lead <i>in vivo<\/i> CAR-M program, comprising a four-component LNP incorporating a novel cationic lipid generated from Liberate\u2019s ML-enabled RAPTOR\u2122 LNP screening platform and an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) designed to reprogram monocytes and macrophages <i>in vivo<\/i>. The presentation expands on Liberate\u2019s previously reported non-human primate data showing selective delivery of CAR-encoding mRNA to monocytes and macrophages drove up to 99% peripheral B-cell depletion at well-tolerated doses. New data from cellular systems, mouse models, and non-human primates further support the mechanism of CAR-expressing myeloid cells as direct effector cells and reinforce the differentiated tolerability profile observed to date, including modest and transient cytokine changes without evidence of T-cell-driven proliferation and other measures of toxicity.<\/p>\n<p>\n\u201cWe\u2019ve made great strides over the last six months on demonstrating the robustness of our novel LNP,\u201d said Walter R. Strapps, Ph.D., Chief Scientific Officer of Liberate Bio. \u201cWe\u2019re able to demonstrate that CAR-expressing myeloid cells can act as effector cells to deplete B-cells in circulation, and we see no evidence of the cytokine spikes that likely drive CRS. We\u2019re excited by the fact that this is a novel approach to target B-cells with a CAR \u2013 one that doesn\u2019t require expressing CAR in T-cells.\u201d<\/p>\n<p>\nLiberate\u2019s proprietary RAPTOR\u2122 platform allows direct screening of lipid nanoparticles (LNPs) in non-human primates to identify delivery vehicles that target extrahepatic cells. The company\u2019s lead LNP is a simple four-component nanoparticle without conjugated targeting moieties that selectively delivers CAR-encoding mRNA to monocytes and macrophages in circulation and bone marrow, creating the potential for a repeatable, systemically administered approach to <i>in vivo <\/i>immune programming.<\/p>\n<p>\nOngoing dose-optimization studies are designed to extend the duration of CAR-M activity and deepen tissue distribution across disease-relevant compartments, including circulation, lymphoid tissue, and bone marrow, to support full-compartment immune reset. Updated data are expected in the second half of 2026.<\/p>\n<p>\n\u201cThe field has seen the promise of <i>in vivo<\/i> CAR-T and the potential to broaden access to this important class of therapeutics, but T-cell programming is not the only path to immune reset,\u201d said Shawn P. Davis, Ph.D., Chief Executive Officer of Liberate Bio. \u201cLIB820 is designed to harness monocytes and macrophages as programmable effector cells \u2014 delivering cell-therapy-like activity through a repeatable, off-the-shelf medicine while avoiding the T-cell activation biology associated with cytokine release syndrome and neurotoxicity. If successful, CAR-M could expand immune programming beyond the most severe patients and into broader autoimmune, oncology, and immune-mediated diseases where CAR-T has not been a practical option.\u201d<\/p>\n<p>\nLiberate plans to support an investigator-initiated trial of LIB820 in diffuse cutaneous systemic sclerosis (dcSSc) in the third quarter of 2026, with proof-of-concept data on B-cell depletion and durability anticipated by the end of 2026. This milestone will mark the transition of Liberate\u2019s platform from preclinical validation to human proof of concept, advancing a new therapeutic class designed to safely reprogram immune cells <i>in vivo<\/i>. The company\u2019s initial clinical focus will include autoimmune indications, such as systemic lupus erythematosus and multiple sclerosis, as well as oncology programs through anti-BCMA CAR-M (LIB810). LIB810 will be explored for the treatment of relapsed\/refractory multiple myeloma (rrMM), in which malignant plasma cells persist primarily in the bone marrow and remain difficult to fully eradicate.<\/p>\n<p>\n<b>Presentation Details<br \/>\n<br \/><\/b><b>Title:<\/b> Precision Engineering of Myeloid Cells In Vivo for Global-Scale Treatments<br \/>\n<br \/><b>Presenter:<\/b> Walter R. Strapps, Ph.D., Chief Scientific Officer, Liberate Bio<br \/>\n<br \/><b>Conference:<\/b> American Society of Gene and Cell Therapies Annual Meeting<br \/>\n<br \/><b>Date and Time:<\/b> May 13, 2026, 4:22 p.m. ET<br \/>\n<br \/><b>Location:<\/b> Boston, Massachusetts<\/p>\n<p>\n<b>About Liberate Bio<\/b><\/p>\n<p>\nLiberate Bio is building the next generation of genetic medicines by solving the most fundamental challenge in the field: delivery beyond the liver. The company\u2019s proprietary RAPTOR\u2122 platform combines high-throughput<i> in vivo<\/i> screening in non-human primates with AI-driven design and optimization, creating the first biological dataset powerful enough to train artificial intelligence on real delivery outcomes.<\/p>\n<p>\nUsing this feedback loop, Liberate Bio has engineered lipid nanoparticles that target specific immune and bone marrow\u2013resident cell types, including monocytes, macrophages, and hematopoietic stem cells (HSCs). This approach enables the programmable delivery of mRNA, gene editing, and other payloads directly to the cells that drive disease \u2014 unlocking the potential to treat oncology, autoimmune, and rare genetic disorders from within the body.<\/p>\n<p>\nLiberate Bio\u2019s first programs focus on <i>in vivo<\/i> CAR-M therapies to reprogram immune cells safely and at scale. Longer term, the company\u2019s platform provides a foundation for a new class of AI-informed, systemically delivered genetic medicines that extend to multiple organs and therapeutic areas.<\/p>\n<p>\nFor more information about the company\u2019s technologies, team, and mission, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.liberatebio.com&amp;esheet=54534383&amp;newsitemid=20260513069585&amp;lan=en-US&amp;anchor=www.liberatebio.com&amp;index=1&amp;md5=d7293a4902687ea169454b08ccb15c78\" rel=\"nofollow\" shape=\"rect\">www.liberatebio.com<\/a><\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nWalter Strapps<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#x69;&#x6c;&#116;&#x6f;&#58;w&#x73;&#116;r&#x61;&#112;p&#x73;&#64;l&#x69;&#98;&#x65;&#x72;&#97;&#x74;&#x65;&#98;&#x69;&#111;&#46;&#x63;&#111;m\" rel=\"nofollow\" shape=\"rect\">&#x77;&#115;t&#x72;&#97;&#112;&#x70;&#x73;&#64;l&#x69;&#98;e&#x72;&#x61;&#116;e&#x62;&#105;o&#x2e;&#x63;&#111;m<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Data expands mechanistic and translational evidence for selective in vivo programming of monocytes and macrophages, potent peripheral B-cell depletion, and a differentiated cytokine profile CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, today announced new pre-clinical data supporting LIB820, the company\u2019s lead in vivo &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-63098","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Data expands mechanistic and translational evidence for selective in vivo programming of monocytes and macrophages, potent peripheral B-cell depletion, and a differentiated cytokine profile CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, today announced new pre-clinical data supporting LIB820, the company\u2019s lead in vivo ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T11:02:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260513069585\/en\/2802829\/22\/Liberate_Bio_Logo_Horizontal-2color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease\",\"datePublished\":\"2026-05-13T11:02:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\\\/\"},\"wordCount\":904,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260513069585\\\/en\\\/2802829\\\/22\\\/Liberate_Bio_Logo_Horizontal-2color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\\\/\",\"name\":\"Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260513069585\\\/en\\\/2802829\\\/22\\\/Liberate_Bio_Logo_Horizontal-2color.jpg\",\"datePublished\":\"2026-05-13T11:02:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260513069585\\\/en\\\/2802829\\\/22\\\/Liberate_Bio_Logo_Horizontal-2color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260513069585\\\/en\\\/2802829\\\/22\\\/Liberate_Bio_Logo_Horizontal-2color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/","og_locale":"en_US","og_type":"article","og_title":"Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease - Pharma Trend","og_description":"Data expands mechanistic and translational evidence for selective in vivo programming of monocytes and macrophages, potent peripheral B-cell depletion, and a differentiated cytokine profile CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, today announced new pre-clinical data supporting LIB820, the company\u2019s lead in vivo ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/","og_site_name":"Pharma Trend","article_published_time":"2026-05-13T11:02:46+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260513069585\/en\/2802829\/22\/Liberate_Bio_Logo_Horizontal-2color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease","datePublished":"2026-05-13T11:02:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/"},"wordCount":904,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260513069585\/en\/2802829\/22\/Liberate_Bio_Logo_Horizontal-2color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/","url":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/","name":"Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260513069585\/en\/2802829\/22\/Liberate_Bio_Logo_Horizontal-2color.jpg","datePublished":"2026-05-13T11:02:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260513069585\/en\/2802829\/22\/Liberate_Bio_Logo_Horizontal-2color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260513069585\/en\/2802829\/22\/Liberate_Bio_Logo_Horizontal-2color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/liberate-bio-presents-new-preclinical-data-supporting-first-clinical-evaluation-of-in-vivo-car-m-program-lib820-in-autoimmune-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=63098"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63098\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=63098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=63098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=63098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}